AI Stock Analysis - Editas Medicine (EDIT)
Analysis generated February 8, 2026.
Editas Medicine is a biotechnology company at the forefront of genome editing. The company uses CRISPR technology to develop treatments for various genetic disorders. Editas' mission is to translate the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome-editing technology into breakthrough human medicines. The company focuses on developing therapies for ocular diseases, oncological conditions, and other genetic challenges.
Stock Alerts - Editas Medicine (EDIT)
 |
Editas Medicine | February 6 Price is up by 6.9% in the last 24h. |
|
Editas Medicine | February 5 Price is down by -6.2% in the last 24h. |
|
Editas Medicine | January 23 Price is down by -6.7% in the last 24h. |
|
Editas Medicine | January 22 Price is up by 6.6% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Editas Medicine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 38 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,092 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 55 | Sign up | Sign up | Sign up |
| Linkedin Employees | 187 | Sign up | Sign up | Sign up |
About Editas Medicine
Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| Price | $1.82 |
| Target Price | Sign up |
| Volume | 1,920,000 |
| Market Cap | $178M |
| Year Range | $1.67 - $4.15 |
| Dividend Yield | 0% |
| Analyst Rating | 24% buy |
| Industry | Biotechnology |
In the news
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and MedicineJanuary 28 - GlobeNewswire |
|
Cell and Gene Therapy Market Poised for US$ 183.1 Billion Growth by 2035 | Astute AnalyticaJanuary 27 - GlobeNewswire |
|
Gene Therapy Investment Trends Strategic Intelligence Report 2026: Market to Reach $42.26 Billion by 2033 | Astute AnalyticaJanuary 27 - GlobeNewswire |
|
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment TrendsJanuary 22 - GlobeNewswire |
|
 |
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialJanuary 12 - Nature.com |
Viral Vector Collaboration and Licensing Agreements Analysis Report 2025: Comprehensive Listing of 413 Viral Vector Deals Announced Since 2016January 5 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 7.5M | 0 | 7.5M | -25M | -22M | -0.280 |
| Q2 '25 | 3.6M | 0 | 3.6M | -53M | -49M | -0.630 |
| Q1 '25 | 4.7M | 910,000 | 4.7M | -76M | -72M | -0.920 |
| Q4 '24 | 31M | 1.4M | 31M | -45M | -33M | -0.550 |
| Q3 '24 | 61,000 | 1.6M | -1.5M | -62M | -61M | -0.750 |
Insider Transactions View All
| Parison Amy filed to sell 15,908 shares at $2.2. December 4 '25 |
| Burkly Linda filed to sell 68,777 shares at $2.2. December 4 '25 |
| O'Neill Gilmore Neil filed to sell 269,087 shares at $2.2. December 4 '25 |
| Parison Amy filed to sell 16,369 shares at $2.6. September 4 '25 |
| Burkly Linda filed to sell 69,490 shares at $2.6. September 4 '25 |
Similar companies
Read more about Editas Medicine (EDIT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Editas Medicine
The Market Cap of Editas Medicine is $178M.
Currently, the price of one share of Editas Medicine stock is $1.82.
The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
